Celcuity is seeing much more options activity than usual, though puts are outweighing calls nine to one as traders appear to bet on a correction. The most popular contract today is the August 25 put, with new positions being bought to open there. The treatment demonstrated a favorable safety profile in comparison to similar drugs, and the triple combo of gedatolisib, Pfizer's (PFE) Ibrance, and AstraZeneca's (AZN) endocrine therapy Faslode reduced the risk of disease progression or death by 76%. Headed for ...